Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease

Annals of Internal Medicine

Volumn 159, Issue 6, 2013, Pages 382-389

  Erickson, Kevin F ^a   Chertow, Glenn M ^a   Goldhaber Fiebert, Jeremy D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOLVAPTAN;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HUMAN; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; POLYURIA; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BENZAZEPINES; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; QUALITY-ADJUSTED LIFE YEARS;

EID: 84884197642     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-6-201309170-00004     Document Type: Article

References (26)

1. U.S. Renal Data System. United States Renal Data System 2011 Annual Data Report. Volume One: Atlas of Chronic Kidney Disease, and Volume 2: End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
2. Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int. 2000;58:925-43. [PMID: 10972657]
3. Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis. 2002;39:1127-34. [PMID: 12046022]
4. Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003;63:678-85. [PMID: 12631134]
5. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-45. [PMID: 8596594]
6. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-84. [PMID: 8114857]
7. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407-18. [PMID: 23121377]
8. Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis. 2001;38:777-84. [PMID: 11576881]
9. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-8. [PMID: 8849754]
10. U.S. Bureau of Labor Statistics. Consumer Price Index-All Urban Consumers. Washington, DC: U.S. Department of Labor; 2011. Accessed at ftp:// ftp.bls.gov/pub/special.requests/cpi/cpiai.txt on 1 November 2012.
11. Thomson PDR. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Reuters; 2010.
12. Centers for Medicare & Medicaid Services. Physician Fee Schedule. Washington, DC: U.S. Department of Health and Human Services; 2011. Accessed at www.cms.gov/apps/physician-fee-schedule/overview.aspx on 15 November 2012.
13. Centers for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule. Washington, DC: U.S. Department of Health and Human Services; 2010. Accessed at www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment /ClinicalLabFeeSched/clinlab.html on 15 November 2012.
14. Arias E. United States life tables, 2006. Natl Vital Stat Rep. 2010;58:1-40. [PMID: 21043319]
15. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305. [PMID: 15385656]
16. Rizk D, Jurkovitz C, Veledar E, Bagby S, Baumgarten DA, Rahbari-Oskoui F, et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009;4:560-6. [PMID: 19261830]
17. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801-8. [PMID: 16316356]
18. Smith DH, Nichols GAN, Gullion CM, Johnson ES, Keith DS. Predicting costs of care in chronic kidney disease: the role of comorbid conditions. The Internet Journal of Nephrology. 2007;4.
19. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102. [PMID: 8483408]
20. Meara E, White C, Cutler DM. Trends in medical spending by age, 1963-2000. Health Aff (Millwood). 2004;23:176-83. [PMID: 15318578]
21. Congressional Budget Office. Prices for Brand-Name Drugs Under Selected Federal Programs. Washington, DC: Congressional Budget Office; 2005. Accessed at www.cbo.gov/sites/default/files/cbofiles/ftpdocs/64xx/doc6481/06-16-prescriptdrug.pdf on 15 November 2012.
22. Perkovic V, Neal B. Trials in kidney disease-time to EVOLVE [Editorial]. N Engl J Med. 2012;367:2541-2. [PMID: 23121375]
23. NKF, FDA to examine new definitions of GFR decline as endpoints in kidney disease trials. Nephrology News & Issues eNews. 27 November 2012. Accessed at www.nephrologynews.com/articles/109165-national-kidney-foundation-fda-to-examine-new-definitions-of-gfr-decline-as-endpoints-in-kidney-disease-trials on 19 December 2012.
24. Earlier endpoints proposed for chronic kidney disease trials. Nephrology News & Issues eNews. 5 December 2012. Accessed at www.nephrologynews.com/articles/109184-Earlier-endpoints-chronic-kidney-disease-trials on 19 December 2012.
25. U.S. Food and Drug Administration. FDA Drug Safety Podcast: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. Washington, DC: U.S. Food and Drug Administration; 2013. Accessed at www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts /ucm350282.htm on 6 May 2013.
26. Tokiwa S, Muto S, China T, Horie S. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2011;15:539-45. [PMID: 21431900]